1-(3-chlorophenyl)piperazine has been researched along with Migraine Disorders in 18 studies
1-(3-chlorophenyl)piperazine: supposed metabolite of TRAZODONE; RN given refers to parent cpd; structure
1-(3-chlorophenyl)piperazine : A N-arylpiperazine that is piperazine carrying a 3-chlorophenyl substituent at position 1. It is a metabolite of the antidepressant drug trazodone.
Migraine Disorders: A class of disabling primary headache disorders, characterized by recurrent unilateral pulsatile headaches. The two major subtypes are common migraine (without aura) and classic migraine (with aura or neurological symptoms). (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ten women with MSM (migraine attacks occurring within 2 days of the onset of menstrual bleeding but lasting more than 72 h) and 9 women with MM (migraine occurring within 2 days of the onset of menstrual bleeding with a typical duration of attacks) were studied." | 2.71 | Neuroendocrine response to the serotonin agonist M-chlorophenylpiperazine in women with menstrual status migrainosus. ( Biancardi, C; Brundu, B; Detaddei, S; Ghiotto, N; Nappi, G; Nappi, RE; Polatti, F; Sances, G, 2003) |
| "Women with OC-status migrainosus showed a derangement of prolactin release (F = 4." | 2.71 | Estradiol supplementation modulates neuroendocrine response to M-chlorophenylpiperazine in menstrual status migrainosus triggered by oral contraception-free interval. ( Brundu, B; De Taddei, S; Ghiotto, N; Nappi, G; Nappi, RE; Polatti, F; Sances, G; Sommacal, A, 2005) |
| "The frequency of these migrainelike headaches was not significantly different between patients with bulimia or anorexia nervosa and control subjects, but incidence of headaches was significantly greater in subjects with a personal or family history of migraine, with almost all predisposed individuals (18 of 20, 90%) developing severe symptoms." | 2.66 | Induction of migrainelike headaches by the serotonin agonist m-chlorophenylpiperazine. ( Brewerton, TD; Jimerson, DC; Mueller, EA; Murphy, DL, 1988) |
| "This model has predictive value for antimigraine drugs but cannot explain the delayed onset of efficacy of 5-HT2B receptor antagonists when clinically used for migraine prophylaxis." | 1.42 | Hypoxia facilitates neurogenic dural plasma protein extravasation in mice: a novel animal model for migraine pathophysiology. ( Andriske, M; Bäcker, I; Dlugosch, E; Hemmer, K; Hunfeld, A; Lübbert, H; Mecheri, B; Paris, F; Segelcke, D; Zhu, X, 2015) |
| "4." | 1.32 | Agonist actions of dihydroergotamine at 5-HT2B and 5-HT2C receptors and their possible relevance to antimigraine efficacy. ( Etienne, N; Guesnier, L; Hickel, P; Maroteaux, L; Schaerlinger, B, 2003) |
| "Although patients with severe migraine-like headaches had higher peak m-CPP levels than patients without severe headaches, these levels are not higher than other groups studied who did not get headaches." | 1.28 | Headache responses following m-chlorophenylpiperazine in bulimics and controls. ( Brandt, HA; Brewerton, TD; Jimerson, DC; Lesem, MD; Murphy, DL, 1992) |
| "1." | 1.28 | The antimigraine drugs ergotamine and dihydroergotamine are potent 5-HT1C receptor agonists in piglet choroid plexus. ( Brown, AM; Kaumann, AJ; Patch, TL, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (11.11) | 18.7374 |
| 1990's | 8 (44.44) | 18.2507 |
| 2000's | 6 (33.33) | 29.6817 |
| 2010's | 2 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schaerlinger, B | 1 |
| Hickel, P | 1 |
| Etienne, N | 1 |
| Guesnier, L | 1 |
| Maroteaux, L | 1 |
| Hunfeld, A | 1 |
| Segelcke, D | 1 |
| Bäcker, I | 1 |
| Mecheri, B | 1 |
| Hemmer, K | 1 |
| Dlugosch, E | 1 |
| Andriske, M | 1 |
| Paris, F | 1 |
| Zhu, X | 1 |
| Lübbert, H | 1 |
| Gorbunov, AA | 1 |
| Gan'shina, TS | 1 |
| Mirzoian, RS | 1 |
| Johnson, KW | 1 |
| Nelson, DL | 1 |
| Dieckman, DK | 1 |
| Wainscott, DB | 1 |
| Lucaites, VL | 1 |
| Audia, JE | 1 |
| Owton, WM | 1 |
| Phebus, LA | 1 |
| Nappi, RE | 2 |
| Sances, G | 2 |
| Brundu, B | 2 |
| Ghiotto, N | 2 |
| Detaddei, S | 1 |
| Biancardi, C | 1 |
| Polatti, F | 2 |
| Nappi, G | 2 |
| De Taddei, S | 1 |
| Sommacal, A | 1 |
| Gordon, ML | 1 |
| Lipton, RB | 1 |
| Brown, SL | 1 |
| Nakraseive, C | 1 |
| Russell, M | 1 |
| Pollack, SZ | 1 |
| Korn, ML | 1 |
| Merriam, A | 1 |
| Solomon, S | 1 |
| van Praag, HM | 1 |
| Kalkman, HO | 1 |
| Leone, M | 2 |
| Attanasio, A | 2 |
| Croci, D | 2 |
| Ferraris, A | 1 |
| D'Amico, D | 2 |
| Grazzi, L | 2 |
| Nespolo, A | 2 |
| Bussone, G | 2 |
| Filippini, G | 1 |
| Martin, RS | 1 |
| Martin, GR | 1 |
| Workman, EA | 1 |
| Tellian, F | 1 |
| Short, D | 1 |
| Brewerton, TD | 2 |
| Murphy, DL | 3 |
| Lesem, MD | 1 |
| Brandt, HA | 1 |
| Jimerson, DC | 2 |
| Silberstein, SD | 1 |
| Fozard, JR | 2 |
| Brown, AM | 1 |
| Patch, TL | 1 |
| Kaumann, AJ | 1 |
| Spierings, EL | 1 |
| Gray, JA | 1 |
| Mueller, EA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of CGRP, Estrogen, Cortisol, VIP, α-Amylase, PGE2, PGI2 and ß-Endorphin Levels in Saliva of Menstrual Migraine Patients Before and After Treatment With Treximet™[NCT01329562] | Phase 4 | 41 participants (Actual) | Interventional | 2011-05-31 | Completed | ||
| Effects of cis9,trans11 Conjugated Linoleic Acid on Platelet Function, Markers of Haemostasis and Inflammation on Humans[NCT01234636] | 50 participants (Actual) | Interventional | 2010-11-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Number of subjects either pain free or mild at 2 hours then pain level increases within 24 hours following treatment with Treximet versus (vs.) Placebo for 1 menstrual migraine.~0-3 pain scale with 0=No Pain, 1=Mild, 2=Moderate,and 3=Severe." (NCT01329562)
Timeframe: From onset of a single menstrual migraine episode to 24 hours post menstrual migraine treatment.
| Intervention | participants (Number) |
|---|---|
| Placebo | 0 |
| Treximet | 2 |
"Number of subjects either pain-free or mild at 2 hours then pain level increases within 24 hours following treatment in Treximet vs. Placebo arm for 1 menstrual migraine headache with Treximet vs. Placebo in responders* vs. non-responders.~0-3 Pain Scale with 0=No Pain, 1=Mild, 2=Moderate, and 3=Severe~*A responder is defined as those who at the time of two hours post treatment reported mild or no pain. Additionally, these subjects could not have taken a rescue medication or have a pain level increase within 24 hours post treatment.~A non-responder is one that fails to meet the responder criteria." (NCT01329562)
Timeframe: From the onset of 1 menstrual migraine until 24 hours post treatment.
| Intervention | participants (Number) |
|---|---|
| Placebo | 1 |
| Treximet Responder | 2 |
| Treximet Non-Responder | 0 |
"Duration of 1 menstrual migraine from time of treatment at menstrual migraine headache onset until pain free in Treximet vs. Placebo arms.~0-3 pain scale with 0=No Pain, 1=Mild, 2=Moderate, and 3=Severe." (NCT01329562)
Timeframe: From onset of 1 menstrual migraine headache until pain free.
| Intervention | hours (Mean) |
|---|---|
| Placebo | 7.64 |
| Treximet | 3.90 |
"Duration of time from treatment at menstrual migraine headache onset until pain-free in Treximet vs. Placebo arms in responders* vs. non-responders for 1 menstrual migraine.~0-3 Pain Scale, with 0=No Pain, 1=Mild, 2=Moderate, and 3=Severe.~*A responder is defined as those who at the time of two hours post treatment reported mild or no pain. Additionally, these subjects could not have taken a rescue medication or have a pain level increase within 24 hours post treatment.~A non-responder is one that fails to meet the responder criteria." (NCT01329562)
Timeframe: From the onset of 1 menstrual migraine headache until pain-free.
| Intervention | hours (Mean) |
|---|---|
| Placebo | 7.64 |
| Treximet Responder | 3.13 |
| Treximet Non-Responder | 4.68 |
"Vasoactive Intestinal Peptide (VIP), Prostaglandin E2 (PGE2), Cortisol, Prostaglandin I2 (PGI2), Estradiol, and β-endorphin** levels collected at Baseline, Menstrual Migraine Headache Onset, and 2 Hours Post Treatment in Treximet vs. Placebo arms for 1 menstrual migraine headache * This endpoint was separated into 3 outcome measures as all biomarkers were not reported in the same units of measure. Calcitonin Gene-Related Peptide (CGRP) and α-amylase both have their own outcome measure reported individually.~**β-endorphin levels were not assayed due to limitations on saliva sample volumes." (NCT01329562)
Timeframe: From Baseline until 2 hours post treatment of 1 menstrual migraine headache
| Intervention | pg/mL (Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VIP Baseline (n=10, 14) | VIP Migraine Onset (n=10, 13) | VIP 2 Hours Post Treatment (n=9, 13) | PGE2 Baseline (n=10, 14) | PGE2 Migraine Onset (n=10, 13) | PGE2 2 Hours Post Treatment (n=9, 14) | Cortisol Baseline (n=10, 13) | Cortisol Migraine Onset (n=8, 13) | Cortisol 2 Hours Post Treatment (n=8, 10) | PGI2 Baseline (n=10, 14) | PGI2 Migraine Onset (n=10, 13) | PGI2 2 Hours Post Treatment (n=9, 14) | Estradiol Baseline (n=10, 13) | Estradiol Migraine Onset (n=9, 13) | Estradiol 2 Hours Post Treatment (n=9,14) | |
| Placebo | 763.6 | 1052.8 | 1130.44 | 9.25 | 7.56 | 8.29 | 1064.14 | 1084.85 | 2011.45 | 109.51 | 108.23 | 97.58 | 63.37 | 41.68 | 54.07 |
| Treximet | 1149.5 | 1111.31 | 933.77 | 12.65 | 13.02 | 7.99 | 1040.49 | 1209.34 | 418.48 | 160.27 | 158.29 | 201.60 | 62.61 | 43.93 | 41.66 |
"VIP, PGE2, Cortisol, PGI2, Estradiol, and β-endorphin** levels collected for 1 menstrual migraine headache at Baseline, Menstrual Migraine Headache Onset, and 2 Hours Post Treatment in Treximet vs. Placebo arms in responders vs. non-responders***.~*This endpoint was separated into 3 outcome measures as all biomarkers were not reported in the same unit of measure. CGRP and α-amylase both have their own outcome measure reported individually.~**β-endorphin levels were not assayed due to limitations on saliva sample volumes.~***A responder is defined as those who at the time of two hours post treatment reported mild or no pain. Additionally, these subjects could not have taken a rescue medication or have a pain level increase within 24 hours post treatment.~A non-responder is one that fails to meet the responder criteria." (NCT01329562)
Timeframe: From Baseline until 2 Hours post menstrual migraine treatment for 1 menstrual migraine headache.
| Intervention | pg/mL (Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VIP Baseline (n=10,7,7) | VIP Migraine Onset (n=10,7,6) | VIP 2 Hours Post Treatment (n=9,7,6,) | PGE2 Baseline (n=10,7,7) | PGE2 Migraine Onset (n=10,7,6) | PGE2 2 Hours Post Treatment (n=9,7,7) | Cortisol Baseline (n=10,6,7) | Cortisol Migraine Onset (n=8,7,6) | Cortisol 2 Hours Post Treatment (n=8,6,4) | PGI2 Baseline (n=10,7,7) | PGI2 Migraine Onset (n=10,7,6) | PGI2 2 Hours Post Treatment (n=9,7,7) | Estradiol Baseline (n=9,7,6) | Estradiol Migraine Onset (n=8,7,6) | Estradiol 2 Hours Post Treatment (n=8,7,7) | |
| Placebo | 763.6 | 1052.8 | 1130.44 | 9.25 | 7.56 | 8.29 | 1064.14 | 1084.5 | 2011.45 | 109.51 | 108.23 | 97.58 | 63.37 | 37.05 | 54.07 |
| Treximet Non-Responder | 885.0 | 948.17 | 414.0 | 11.01 | 11.72 | 9.15 | 1254.53 | 1508.97 | 322.72 | 177.54 | 186.17 | 247.63 | 66.68 | 42.81 | 46.68 |
| Treximet Responder | 1414.0 | 1251.14 | 1320.14 | 14.29 | 14.13 | 6.83 | 790.77 | 952.52 | 482.32 | 142.99 | 134.40 | 155.56 | 49.60 | 44.89 | 36.64 |
"VIP, PGE2, Cortisol, PGI2, Estradiol, and β-endorphin** levels collected for 1 menstrual migraine headache at Menstrual Migraine Headache Onset, Migraine Headache Free, and 24 Hours Migraine Headache Free in Responders vs Non-Responders***.~*This endpoint was separated into 3 outcome measures as all biomarkers were not reported in the same units of measure. CGRP and α-amylase both have their own outcome measure reported individually.~**β-endorphin levels were not assayed due to limitations on saliva sample volumes.~***A responder is defined as those who at the time of two hours post treatment reported mild or no pain. Additionally, these subjects could not have taken a rescue medication or have a pain level increase within 24 hours post treatment. A non-responder is one that fails to meet the responder criteria." (NCT01329562)
Timeframe: From Baseline for the duration of 1 menstrual migraine headache, an estimated 7 days
| Intervention | pg/mL (Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VIP Migraine Onset (n=10,7,6) | VIP Migraine Headache Free (n=9,4,6) | VIP 24 Hours Migraine Headache Free (n=10,7,5) | PGE2 Migraine Onset (n=10,7,6) | PGE2 Migraine Headache Free (n=10,4,6) | PGE2 24 Hours Migraine Headache Free (n=10,7,7) | Cortisol Migraine Onset (n=8,7,6) | Cortisol Migraine Headache Free (n=10,3,5) | Cortisol 24 Hours Migraine Headache Free(n=10,6,6) | PGI2 Migraine Onset (n=10,7,6) | PGI2 Migraine Headache Free (n=10,4,6) | PGI2 24 Hours Migraine Headache Free (n=10,7,7) | Estradiol Migraine Onset (n=9,7,6) | Estradiol Migraine Headache Free (n=9,5,4) | Estradiol 24 Hours Migraine Headache Free(n=6,7,6) | |
| Placebo | 105.28 | 964.4 | 1059.9 | 7.56 | 8.35 | 10.46 | 1084.5 | 1490.92 | 1031.16 | 108.23 | 115.63 | 97.69 | 37.75 | 48.83 | 21.34 |
| Treximet Non-Responder | 948.97 | 643.0 | 1174.2 | 11.72 | 10.21 | 12.65 | 1508.97 | 2042.87 | 1621.38 | 186.17 | 176.37 | 295.07 | 42.81 | 26.58 | 81.38 |
| Treximet Responder | 1251.14 | 1409.75 | 1480.79 | 14.13 | 7.87 | 13.43 | 952.52 | 592.35 | 863.09 | 134.40 | 154.16 | 154.10 | 44.89 | 56.59 | 34.86 |
"VIP, PGE2, Cortisol, PGI2, Estradiol, and β-endorphin** levels collected at Menstrual Migraine Headache Onset, Migraine Headache Free and 24 Hours Migraine Headache Free in Treximet vs. Placebo arm for 1 menstrual migraine headache.~* This endpoint was separated into 3 outcome measures as all biomarkers were not reported in the same units of measure. CGRP and α-amylase both have their own outcome measure reported individually.~**β-endorphin levels were not assayed due to limitations on saliva sample volumes." (NCT01329562)
Timeframe: From baseline to 24 hours post headache gone for 1 menstrual migraine headache.
| Intervention | pg/mL (Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VIP Migraine Onset (n=10,7,6) | VIP Migraine Headache Free (n=9,4,7) | VIP 24 Hours Migraine Headache Free (n=10,7,6) | PGE2 Migraine Onset (n=10,7,6) | PGE2 Migraine Headache Free (n=10,4,6,) | PGE2 24 Hours Migraine Headache Free (n=10,7,7) | Cortisol Migraine Onset (n=8,7,6) | Cortisol Migraine Headache Free (n=10,3,6) | Cortisol 24 Hours Migraine Headache Free(n=10,6,6) | PGI2 Migraine Onset (n=10,7,6) | PGI2 Migraine Headache Free (n=10,4,6) | PGI2 24 Hours Migraine Headache Free (n=10,7,7) | Estradiol Migraine Onset (n=9,7,6) | Estradiol Migraine Headache Free (n=9,4,5,) | Estradiol 24 Hours Migraine Headache Free(n=6,7,5) | |
| Placebo | 1052.8 | 964.4 | 1059.9 | 7.56 | 8.35 | 10.46 | 1084.5 | 1490.92 | 1031.16 | 108.23 | 115.63 | 97.69 | 37.05 | 48.83 | 21.34 |
| Treximet | 1111.31 | 949.7 | 1353.04 | 13.02 | 9.27 | 13.04 | 1209.34 | 1498.92 | 1271.4 | 158.29 | 167.48 | 224.58 | 43.93 | 39.92 | 56.33 |
"CGRP levels collected at Baseline, Menstrual Migraine Headache Onset, and 2 Hours Post Treatment in Treximet vs. Placebo arms for 1 menstrual migraine headache~* This endpoint was separated into 3 outcome measures as all biomarkers were not reported in the same units of measure." (NCT01329562)
Timeframe: From Baseline until 2 hours post treatment for 1 menstrual migraine headache
| Intervention | pmol/mg (Mean) | ||
|---|---|---|---|
| CGRP Baseline (n=10, 14) | CGRP Migraine Onset (n=10, 13) | CGRP 2 Hours Post Treatment (n=9, 14) | |
| Placebo | 18.55 | 22.28 | 14.92 |
| Treximet | 15.03 | 27.82 | 21.38 |
"CGRP levels collected for 1 menstrual migraine headache at Baseline, Menstrual Migraine Headache Onset, and 2 Hours Post-Treatment in Responders vs Non-Responders**.~*This endpoint was separated into 3 outcome measures as all biomarkers were not reported in the same units of measure.~**A responder is defined as those who at the time of two hours post treatment reported mild or no pain. Additionally, these subjects could not have taken a rescue medication or have a pain level increase within 24 hours post treatment.~A non-responder is one that fails to meet the responder criteria." (NCT01329562)
Timeframe: From Baseline until 2 Hours post menstrual migraine treatment for 1 menstrual migraine headache.
| Intervention | pmol/mg (Mean) | ||
|---|---|---|---|
| CGRP Baseline (n=10,7,7) | CGRP Migraine Onset (n=10,7,6) | CGRP 2 Hours Post Treatment (n=9,7,7) | |
| Placebo | 18.55 | 22.28 | 14.92 |
| Treximet Non-Responder | 17.80 | 33.76 | 21.67 |
| Treximet Responder | 12.27 | 22.74 | 21.08 |
"CGRP levels collected at Menstrual Migraine Headache Onset, Migraine Headache Free, and 24 Hours Migraine Headache Free in Treximet vs. Placebo arm for 1 menstrual migraine headache.~* This endpoint was separated into 3 outcome measures as all biomarkers were not reported in the same units of measure." (NCT01329562)
Timeframe: From baseline to 24 hours post headache gone for 1 menstrual migraine headache
| Intervention | pmol/mg (Mean) | ||
|---|---|---|---|
| CGRP Migraine Onset (n=10,7,6) | CGRP Migraine Headache Free (n=9,4,6) | CGRP 24 Hours Migraine Headache Free (n=9,7,7) | |
| Placebo | 22.28 | 22.55 | 29.37 |
| Treximet | 28.82 | 32.26 | 32.15 |
"CGRP levels collected for 1 menstrual migraine headache at Menstrual Migraine Headache Onset, Migraine Headache Free, and 24 Hours Migraine Headache Free in Responders vs Non-Responders**.~*This endpoint was separated into 3 outcome measures as all biomarkers were not reported in the same units of measure.~**A responder is defined as those who at the time of two hours post treatment reported mild or no pain. Additionally, these subjects could not have taken a rescue medication or have a pain level increase within 24 hours post treatment.~A non-responder is one that fails to meet the responder criteria." (NCT01329562)
Timeframe: From Baseline to 24 hours post headache gone for 1 menstrual migraine.
| Intervention | pmol/mg (Mean) | ||
|---|---|---|---|
| CGRP Migraine Onset (n=10,7,6) | CGRP Migraine Headache Free (n=9,4,6) | CGRP 24 Hours Migraine Headache Free (n=9,7,7) | |
| Placebo | 22.28 | 22.55 | 29.37 |
| Treximet Non-Responder | 33.76 | 20.78 | 35.87 |
| Treximet Responder | 22.74 | 49.48 | 28.43 |
"Correlation of mean estrogen levels in saliva and urine estradiol at mid luteal, menstrual migraine headache onset*, and at migraine headache free following treatment with Treximet vs. Placebo for 1 menstrual migraine headache~*Urine estradiol levels were not collected at migraine onset, therefore; correlations could not be completed for that time point." (NCT01329562)
Timeframe: From mid luteal phase and for the duration of 1 menstrual migraine headache and until headache free
| Intervention | pg/mL (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Urine Pre-Cycle Day 1 (n=3, 6) | Urine Pre-Cycle Day 2 (n=6, 8) | Urine Pre-Cycle Day 3 (n=8, 6) | Urine Pre-Cycle Day 4 (n=9, 10) | Urine Migraine Headache Free (n=11, 13 | Saliva Pre-Cycle Day 1 (n=1, 4) | Saliva Pre-Cycle Day 2 (n=2, 6) | Saliva Pre-Cycle Day 3 (n=8, 10) | Saliva Pre-Cycle Day 4 (n=6, 9) | Saliva Migraine Headache Free (n=8, 6) | |
| Placebo | 2442.44 | 4333.92 | 3582.92 | 3232.10 | 2398.55 | 41.75 | 63.45 | 46.47 | 55.86 | 54.93 |
| Treximet | 3090.92 | 2616.64 | 5089.63 | 3141.51 | 2989.72 | 43.33 | 41.87 | 73.08 | 41.72 | 51.32 |
"Correlation of mean estrogen levels in saliva and urine estradiol at mid-luteal, menstrual migraine headache onset* and at migraine headache free following treatment in responders vs. non-responders**.~*Urine estradiol levels were not collected at migraine onset, therefore; correlations could not be completed for that time point.~***A responder is defined as those who at the time of two hours post treatment reported mild or no pain. Additionally, these subjects could not have taken a rescue medication or have a pain level increase within 24 hours post treatment.~A non-responder is one that fails to meet the responder criteria." (NCT01329562)
Timeframe: From mid luteal phase and for the duration of 1 menstrual migraine until headache free.
| Intervention | pg/mL (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Urine Pre-Cycle Day 1 (n=3,2,4) | Urine Pre-Cycle Day 2 (n=6,3,5) | Urine Pre-Cycle Day 3 (n=8,2,5) | Urine Pre-Cycle Day 4 (n=9,5,5) | Urine Migraine Headache Free (n=10,7,7) | Saliva Pre-Cycle Day 1 (n=1,0,4) | Saliva Pre-Cycle Day 2 (n=2,2,4) | Saliva Pre-Cycle Day 3 (n=8,4,7) | Saliva Pre-Cycle Day 4 (n=8,5,4) | Saliva Migraine Headache Free (n=8,3,4) | |
| Placebo | 2442.44 | 4333.92 | 3582.92 | 3232.10 | 2398.55 | 41.75 | 63.45 | 46.47 | 55.86 | 54.93 |
| Treximet Non-Responder | 3687.07 | 3661.52 | 5629.71 | 4266.02 | 3373.40 | 43.33 | 47.36 | 67.76 | 54.22 | 33.22 |
| Treximet Responder | 1898.63 | 875.34 | 3739.44 | 2016.99 | 2542.09 | NA | 30.89 | 81.05 | 31.71 | 75.45 |
"α-Amylase levels collected at Baseline, Menstrual Migraine Headache Onset, and 2 Hours Post Treatment in Treximet vs. Placebo arm for 1 menstrual migraine headache~* This endpoint was separated into 3 outcome measures as all biomarkers were not reported in the same units of measure." (NCT01329562)
Timeframe: From Baseline until 2 hours post treatment for 1 menstrual migraine headache
| Intervention | U/L (Mean) | ||
|---|---|---|---|
| α-Amylase Baseline (n=10, 14) | α-Amylase Migraine Onset (n=10, 13) | α-Amylase 2 Hours Post Treatment (n=9, 14) | |
| Placebo | 109280.50 | 100956.70 | 102449.80 |
| Treximet | 99626.61 | 98853.32 | 103594.90 |
"α-Amylase levels collected at Baseline, Menstrual Migraine Headache Onset, and 2 Hours Post Treatment in Responders vs Non-Responders*.~*A responder is defined as those who at the time of two hours post treatment reported mild or no pain. Additionally, these subjects could not have taken a rescue medication or have a pain level increase within 24 hours post treatment.~A non-responder is one that fails to meet the responder criteria." (NCT01329562)
Timeframe: From Baseline until 2 hours post treatment of 1 menstrual migraine headache.
| Intervention | U/L (Mean) | ||
|---|---|---|---|
| α-Amylase Baseline (n=10,7,7) | α-Amylase Migraine Onset (n=10,7,6) | α-Amylase 2 Hours Post Treatment (n=9,7,7) | |
| Placebo | 109280.50 | 100956.7 | 102449.88 |
| Treximet Non-Responder | 101250.54 | 93456.77 | 103662.4 |
| Treximet Responder | 98002.68 | 103478.94 | 103527.5 |
"α-Amylase levels collected at Menstrual Migraine Headache Onset, Migraine Headache Free, and 24 Hours Migraine Headache Free in Treximet vs. Placebo arm for 1 menstrual migraine headache~* This endpoint was separated into 3 outcome measures as all biomarkers were not reported in the same units of measure." (NCT01329562)
Timeframe: From baseline to 24 hours post headache gone for 1 menstrual migraine headache
| Intervention | U/L (Mean) | ||
|---|---|---|---|
| α-Amylase Migraine Onset (n=10,7,6) | α-Amylase Migraine Headache Free (n=10,4,6) | α-Amylase 24 Hours Migraine Headache Free(n=10,7,7 | |
| Placebo | 100956.70 | 102908.61 | 100354.00 |
| Treximet | 98853.32 | 101307.25 | 102017.80 |
"α-Amylase levels collected for 1 menstrual migraine at Menstrual Migraine Headache Onset, Migraine Headache Free, and 24 Hours Migraine Headache Free in Responders vs Non-Responders**.~*This endpoint was separated into 3 outcome measures as all biomarkers were not reported in the same units of measure.~**A responder is defined as those who at the time of two hours post treatment reported mild or no pain. Additionally, these subjects could not have taken a rescue medication or have a pain level increase within 24 hours post treatment.~A non-responder is one that fails to meet the responder criteria." (NCT01329562)
Timeframe: From Baseline from 24 hours post migraine gone for 1 menstrual migraine.
| Intervention | U/L (Mean) | ||
|---|---|---|---|
| α-amylase Migraine Onset (n=10,7,6) | α-amylase Migraine Headache Free (n=9,7,7) | α-amylase 24 Hours Migraine Headache Free(n=10,4,6 | |
| Placebo | 100956.7 | 102908.61 | 100354.3 |
| Treximet Non-Responder | 93456.77 | 103031.44 | 101559.9 |
| Treximet Responder | 103478.94 | 98720.95 | 102475.8 |
3 reviews available for 1-(3-chlorophenyl)piperazine and Migraine Disorders
| Article | Year |
|---|---|
Hypersensitivity to meta-chlorophenylpiperazine (mCPP) in migraine and drug withdrawal.
Topics: Animals; Depression; Humans; Migraine Disorders; Piperazines; Rats; Serotonin Receptor Agonists; Spe | 1997 |
Hypothesis: serotonin-1C receptor activation in migraine: an alternative point of view with therapeutic implication.
Topics: Humans; Migraine Disorders; Piperazines; Receptors, Serotonin; Vasoconstrictor Agents; Vasodilator A | 1991 |
5-HT1C receptor activation: a key step in the initiation of migraine?
Topics: Female; Humans; Migraine Disorders; Piperazines; Receptors, Serotonin | 1989 |
6 trials available for 1-(3-chlorophenyl)piperazine and Migraine Disorders
| Article | Year |
|---|---|
Neuroendocrine response to the serotonin agonist M-chlorophenylpiperazine in women with menstrual status migrainosus.
Topics: Adult; Animals; Female; Humans; Hydrocortisone; Menstrual Cycle; Migraine Disorders; Piperazines; Pr | 2003 |
Estradiol supplementation modulates neuroendocrine response to M-chlorophenylpiperazine in menstrual status migrainosus triggered by oral contraception-free interval.
Topics: Administration, Cutaneous; Adult; Analysis of Variance; Body Mass Index; Contraceptives, Oral; Contr | 2005 |
Headache and cortisol responses to m-chlorophenylpiperazine are highly correlated.
Topics: Adult; Double-Blind Method; Female; Headache; Humans; Hydrocortisone; Male; Migraine Disorders; Pipe | 1993 |
5-HT1A receptor hypersensitivity in migraine is suggested by the m-chlorophenylpiperazine test.
Topics: Adult; Anxiety; Female; Humans; Hydrocortisone; Male; Migraine Disorders; Piperazines; Prolactin; Re | 1998 |
The serotonergic agent m-chlorophenylpiperazine induces migraine attacks: A controlled study.
Topics: Adult; Double-Blind Method; Female; Humans; Male; Migraine Disorders; Pain Measurement; Piperazines; | 2000 |
Induction of migrainelike headaches by the serotonin agonist m-chlorophenylpiperazine.
Topics: Adult; Female; Humans; Migraine Disorders; Piperazines; Receptors, Serotonin | 1988 |
9 other studies available for 1-(3-chlorophenyl)piperazine and Migraine Disorders
| Article | Year |
|---|---|
Agonist actions of dihydroergotamine at 5-HT2B and 5-HT2C receptors and their possible relevance to antimigraine efficacy.
Topics: Amphetamines; Animals; Binding, Competitive; Cell Line; Cyclic GMP; Dihydroergotamine; Humans; Inosi | 2003 |
Hypoxia facilitates neurogenic dural plasma protein extravasation in mice: a novel animal model for migraine pathophysiology.
Topics: Animals; Blood Proteins; Disease Models, Animal; Dura Mater; Female; Guinea Pigs; Hypoxia; Male; Mic | 2015 |
[Effect of tropoxin on cerebrovascular effects of meta-chlorophenylpiperazine and serotonin].
Topics: Animals; Aza Compounds; Blood Pressure; Bridged Bicyclo Compounds, Heterocyclic; Carotid Artery, Int | 2010 |
Neurogenic dural protein extravasation induced by meta-chlorophenylpiperazine (mCPP) involves nitric oxide and 5-HT2B receptor activation.
Topics: Animals; Blood Proteins; Brain; Dose-Response Relationship, Drug; Dura Mater; Electric Stimulation; | 2003 |
Investigations into migraine pathogenesis: time course for effects of m-CPP, BW723C86 or glyceryl trinitrate on appearance of Fos-like immunoreactivity in rat trigeminal nucleus caudalis (TNC).
Topics: Animals; Genes, fos; Indoles; Migraine Disorders; Nitric Oxide; Nitroglycerin; Piperazines; Rats; Se | 2001 |
Trazodone induction of migraine headache through mCPP.
Topics: Adult; Depressive Disorder; Humans; Male; Migraine Disorders; Piperazines; Trazodone | 1992 |
Headache responses following m-chlorophenylpiperazine in bulimics and controls.
Topics: Anorexia Nervosa; Bulimia; Female; Humans; Migraine Disorders; Piperazines; Reference Values | 1992 |
More on mCPP and migraine.
Topics: Humans; Migraine Disorders; Piperazines | 1992 |
The antimigraine drugs ergotamine and dihydroergotamine are potent 5-HT1C receptor agonists in piglet choroid plexus.
Topics: Animals; Binding, Competitive; Choroid Plexus; Dihydroergotamine; Ergolines; Ergotamine; In Vitro Te | 1991 |